Latest News
and Innovations

Nov 20, 2024

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH

Nov 18, 2024

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

Nov 6, 2024

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

Nov 1, 2024

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 28, 2024

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November

VIEW ALL NEWS
add animation
An anatomical heartAn anatomical heart

Driven by Patient Need,
Guided by Expertise

At NewAmsterdam Pharma, we are advancing a
new era of treatments for cardiovascular disease
(CVD) and other lipid-related conditions. By
prioritizing patients with unmet needs despite
currently available therapies, we are working
toward a reality where cardiovascular disease is no
longer the #1 killer of people worldwide.

LEARN MORE ABOUT US
A couple embracingA couple embracing

Developing a
Transformational Program

Guided by the latest clinical science and genetic research on CETP inhibition, our investigational asset, obicetrapib, was selected based on its potential ability to lower LDL-C and reduce cardiovascular risk.

DISCOVER OBICETRAPIB
Someone using a pipette to drop something in a petri dish